Sector News

Sunshine Act payment data leaves out newly influential prescribers

July 8, 2015
Life sciences
The Physician Payments Sunshine Act was meant to shine a light on pharma’s payments to doctors, boosting transparency and potentially reducing unsavory business practices. But the act leaves out a big chunk of prescribers: nurse practitioners and physician assistants (PAs).
 
As NPR reports, nurse practitioners and PAs play an increasingly large role in healthcare, taking on many of the same tasks as doctors. PAs and nurses wrote about 10% of the nearly 1.4 billion prescriptions in Medicare’s prescription drug program in 2013, according to a ProPublica analysis cited by NPR. The two groups wrote 15% of all scripts nationwide during the first 5 months of the same year, an IMS Health study notes.
 
While pharma’s relationships with doctors have historically drawn the most attention, nurses’ interactions with the industry have “as much relevance,” Dr. Walid Gellad, co-director of the University of Pittsburgh’s Center for Pharmaceutical Policy and Prescribing, told the news outlet. “If the purpose of the act is to shine a light on the relationship between industry and the healthcare sector, then you’ve left out an important component of that sector,” he said.
 
When the Sunshine Act was drafted, nursing groups weren’t covered by the law and thus weren’t a part of policy discussions, Allan Coukell, senior director for health programs at the Pew Charitable Trusts, told NPR. But just because that’s how the system worked in the past doesn’t mean it should continue in the same vein, he added.
 
“(T)o the extent that a lot of prescribing now is done by health professionals who aren’t physicians, and a lot of marketing is directed at them, they ideally should also be part of the disclosure,” Coukell said (as quoted by NPR).
 
Meanwhile, the industry has slowly begun to change its tune when it comes to interactions with healthcare providers. In 2013, GlaxoSmithKline CEO Andrew Witty pledged to end doctor payments by 2016 to give the company’s image a much-needed boost. While the company has yet to make big moves in that department, GSK plans to roll out a new suite of services by 2016 to replace paid speakers, loosening its ties with doctors. “We expect overall payments to continue decreasing as we continue to implement our new approach to working with healthcare professionals,” company spokeswoman Sarah Alspach told Bloomberg last month.
 
By Emily Wasserman
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”